Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
American WellAMWL +0.17%50 Debt-to-EBITDA is -0.29 as of Jun. 2026. GuruFocus rates AMWL with a GF Score™ of 50/100 and a GF Value™ of $6.41 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 480 Healthcare Providers & Services companies, American Well ranks worse than 208333.13% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for American Well's Debt-to-EBITDA or its related term are showing as below:
AMWL'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.15 Med: -0.06 Max: -0.04
Current: -0.06
During the past 8 years, the highest Debt-to-EBITDA Ratio of American Well was -0.04. The lowest was -0.15. And the median was -0.06.
AMWL's Debt-to-EBITDA is ranked worse than 100% of 480
companies
in the Healthcare Providers & Services industry
Industry Median: 2.185
vs AMWL: -0.06
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
American Well Debt-to-EBITDA Related Terms
American Well Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for American Well's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, American Well's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
American Well Debt-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, American Well's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where American Well's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.
American Well (AMWL) has a Debt-to-EBITDA of -0.29 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on American Well. According to the industry distribution chart, American Well ranks #999999 out of 480 companies in the Healthcare Providers & Services industry.
Is American Well's Debt-to-EBITDA too high?
American Well's current Debt-to-EBITDA is -0.29. Based on the distribution chart, American Well ranks #999999 out of 480 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, American Well has a GF Score™ of 50/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does American Well's Debt-to-EBITDA compare to LFMD and SY?
According to the Healthcare Providers & Services industry distribution chart, American Well ranks #999999 out of 480 companies for Debt-to-EBITDA. This places American Well in the lower half of its industry. The industry median Debt-to-EBITDA is 2.19. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Healthcare Providers & Services company?
The median Debt-to-EBITDA among Healthcare Providers & Services companies is 2.19, based on 480 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on American Well. For the Healthcare Providers & Services industry, the median Debt-to-EBITDA is 2.19 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. American Well's current Debt-to-EBITDA is -0.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is American Well stock overvalued right now?
Based on GuruFocus' analysis, American Well (AMWL) is currently considered Significantly Overvalued. The stock's GF Value™ is $6.41, compared to a current price of $11.92 — trading 86% above its estimated fair value. The current Debt-to-EBITDA is -0.29. American Well's overall GF Score™ is 50/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For American Well (AMWL), the current Debt-to-EBITDA is -0.29 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is American Well (AMWL) Overvalued in 2026?
Based on GuruFocus' analysis, American Well stock appears to be overvalued.
The current stock price of $11.92 is trading 86% above its estimated GF Value™ of $6.41.
GuruFocus considers American Well to be Significantly Overvalued.
Key valuation signals for AMWL:
Debt-to-EBITDA: -0.29
GF Value™: $6.41 vs. price of $11.92 (86% above fair value)
No single metric tells the full story. See the AMWL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
American Well Corp is an enterprise platform and software company digitally enabling hybrid care by offering payers and health systems a technology-enabled care platform. The Amwell Platform, its cloud-based enablement platform, digitally enables a scalable healthcare experience across all care settings by enabling critical services like virtual primary care, urgent care, clinical partner programs, scheduling visits, etc. Additionally, the healthcare providers can use the platform to access familiar workflows for taking notes, prescribing, referencing clinical treatment guidelines, and other related activities. The firm also offers various paid services, including licensed clinical staffing, implementation support, workflow design, etc, to help clients execute their hybrid care strategies.
50GF Score
Get the complete analysis for AMWL
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AMWL has been successfully added to your 
